Advicenne Shareholders Approve Board-Supported Resolutions at General Meeting

Advicenne (Euronext Growth Paris: ALDVI), a specialty pharmaceutical company focusing on rare renal diseases, announced that its Combined General Meeting on May 14, 2024, successfully adopted all board-supported resolutions. The meeting, held in Paris, addressed key issues such as statutory financial statement approvals, financial delegations to the Board of Directors, and the allocation of share warrants. One resolution, the 16th, was notably rejected as recommended by the Board. Further details continue to be accessible on the company's investor relations webpage.